Pancreatic Cancer Test Tapped for Landmark UK Study
ClearNote Health collaborates with research teams in Southampton, UK, to use their Avantect Pancreatic Cancer Test in a large-scale study.
ClearNote Health collaborates with research teams in Southampton, UK, to use their Avantect Pancreatic Cancer Test in a large-scale study.
Immunovia's new pancreatic cancer test demonstrated a specificity of 98% and a sensitivity of 75% for early-stage 1 and 2 pancreatic cancers.
A research team identified biomarkers that could help distinguish whether cysts on the pancreas will develop into cancer or remain benign.
Personalis and BC Cancer will deploy a personalized liquid biopsy-based assay for a study of patients with colorectal and pancreatic cancers.
Read MorePancreatic ductal adenocarcinoma affects more than 90% of patients with pancreatic cancer and has an average 5-year survival rate under 10%.
Read MoreResearchers have found a molecular signature in stool samples that could predict whether patients are at high risk of pancreatic cancer.
Read MoreYale Cancer Center early detection research is providing new reason for optimism for the diagnosis of pancreatic cancer.
Read MoreBluestar Genomics’ liquid biopsy test can detect a pancreatic cancer signal in people across various age groups and in patients with new-onset diabetes.
Read MoreNew research showed that blood tests may be the future of pancreatic cancer detection. Pancreatic cancer is one of the most deadly forms of the disease.
Read MoreResearchers from Johns Hopkins and an international team, have identified promising new targets for pancreatic cancer treatment and early diagnosis.
Read MoreResearchers from Queen Mary University of London have identified a protein that could be used to aid in the diagnosis of pancreatic cancer.
Read MorePanCAN has chosen to upgrade to GenomOncology’s Precision Decision to further enhance the free clinical trial matching services it offers to pancreatic cancer patients.
Read MoreThe AI-based tool for predicting genomic subtypes of PDAC can be used in clinical practice worldwide for patient stratification.
Read MoreAn odor-based test that sniffs out vapors emanating from blood samples was able to distinguish cancer cells with up to 95% accuracy.
Read MorecfDNA-based liquid biopsy analysis of KRAS mutations using OncoBEAM technology can assist in the prognosis determination and management of PDAC patients.
Read MoreCaris will provide DNA and RNA molecular testing to support patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trial.
Read MorePenn study shows liquid biopsy may be viable option for both diagnosis and disease staging of pancreatic cancer.
Read MoreThe blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read More